Market News

POINT Biopharma (NASDAQ: PNT) Down After Stock Offering

POINT Biopharma Global (NASDAQ: PNT) was down in pre-market trading on Wednesday after the company that develops and discovers radiopharmaceuticals proposed a public offering of 13.9 million shares at a price of $9 per share.

The gross proceeds from this offering are expected to be around $125 million and the offering is expected to close on or about September 16.

POINT is also offering the underwriters “a 30-day option to purchase up to an additional 2,085,000 shares of its Common Stock.”

Is POINT Biopharma a Buy?

Analysts are bullish about POINT Biopharma with a Strong Buy consensus rating based on six unanimous Buys.

PNT’s average price prediction of $20.75 implies that the stock has an upside potential of around 104%.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More